Biontech Se

Tron—translationale Onkologie An Der Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Ggmbh

Biontech Rna Pharmaceuticals Gmbh

Biontech Ag

Uniwersytet Warszawski

Tron—translationale Onkologie An Der Universitátsmedizin Der Johannes Gutenberg—universitÄt Mainz Gemeinnützige Gmbh

Andreas Kuhn

Ugur Sahin

Özlem Türeci

Alexander Muik

Britta Vallazza

Kerstin Walzer

Annette Vogel

Alptekin Güler

Stephanie Hein

Sonja Witzel

Mustafa Diken

Stephanie Fesser

Tim Beissert

Marco Alexander Poleganov

Jacek Jemielity

Joanna Kowalska

Edward Darzynkiewicz

Florian Eberle

Alexandra Orlandini Von Niessen

Johanna Drögemüller

Jenna Kathryn Williamson

Jennifer Ann Schoborg Romine

Rodney Gene Combs

Maximilian Buff

Irena Rabe

Katalin Kariko

Hiromi Muramatsu

Nicole Star Eschmann

Thomas Ziegenhals

The present disclosure provides technologies for in vitro transcription reactions, particularly for production of pharmaceutical grade RNA, and in some embodiments for large scale production.

In vitro transcription technologies

The present invention relates to 5'-cap compounds, in particular the stabilization of RNA by such 5′-cap compounds, and provides compositions, such as pharmaceutical compositions, and cells comprising an RNA which is modified with such a 5′-cap compound, as well as methods for producing a peptide or protein of interest using the compositions or cells according to the present invention. Furthermore, the present invention provides the RNA, compositions, or cells for use in therapy, in particular for use in a method of treating a disease or disorder by protein replacement therapy, genome engineering, genetic reprogramming, and immunotherapy; a method for increasing the stability of RNA in cells; a method for increasing the expression of RNA in cells; and a method for providing an RNA with a 5′-cap structure.

5'-cap-trinucleotide- or higher oligonucleotide compounds and their use in stabilizing RNA, expressing proteins in therapy

This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

Coronavirus vaccine

The present invention relates to nucleic acid molecules containing poly (dA:dT) regions which are stabilized in.-, methods of propagating such nucleic acid molecules in, methods of obtaining RNA, peptides or proteins using such nucleic acid molecules and to RNA which is obtained from such nucleic acid molecules and its use. In particular, the poly (dA:dT) regions contain at least one disruption by a sequence not encoding a sequence solely composed of A residues.

Stabilization of poly(A) sequence encoding DNA sequences

This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject. i.e., vaccine RNA encoding vaccine antigen.

The present invention relates to stabilization of RNA, in particular mRNA, and an increase in mRNA translation. The present invention particularly relates to a modification of RNA, in particular in vitro-transcribed RNA, resulting in increased transcript stability and/or translation efficiency. According to the invention, it was demonstrated that certain sequences in the 3'-untranslated region (UTR) of an RNA molecule improve stability and translation efficiency.

3'-UTR sequences for stabilization of RNA

The present invention relates to nucleic acid molecules containing poly (dA:dT) regions which are stabilized in, methods of propagating such nucleic acid molecules in, methods of obtaining RNA, peptides or proteins using such nucleic acid molecules and to RNA which is obtained from such nucleic acid molecules and its use. In particular, the poly (dA:dT) regions contain at least one disruption by a sequence not encoding a sequence solely composed of A residues.

The present invention relates to modification of RNA with 5'-cap analogs of Formula (1): wherein R-Rand n are as described herein, in order to improve the stability and increase the expression of said RNA, in particular in immature antigen presenting cells. The present invention provides a vaccine composition comprising said stabilized RNA, immature antigen presenting cells comprising said stabilized RNA, and methods for stimulating and/or activating immune effector cells and for inducing an immune response in an individual using said stabilized RNA.

Vaccine composition comprising 5'-cap modified RNA

Growing community of inventors

Mainz, Germany

Andreas Kuhn